CN120225225A - 去泛素化酶靶向性嵌合体及相关方法 - Google Patents

去泛素化酶靶向性嵌合体及相关方法 Download PDF

Info

Publication number
CN120225225A
CN120225225A CN202280032073.1A CN202280032073A CN120225225A CN 120225225 A CN120225225 A CN 120225225A CN 202280032073 A CN202280032073 A CN 202280032073A CN 120225225 A CN120225225 A CN 120225225A
Authority
CN
China
Prior art keywords
tautomer
stereoisomer
solvate
pharmaceutically acceptable
hydrate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280032073.1A
Other languages
English (en)
Chinese (zh)
Inventor
L·博伊克
D·L·多瓦拉
N·J·海宁
M·J·海塞
G·刘
J·M·麦肯纳
D·K·诺姆拉
M·E·席勒
J·N·斯普拉德林
J·A·塔拉里科
C·C·沃德
M·皮盖蒂
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
University of California, San Diego
Original Assignee
Novartis AG
University of California, San Diego
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG, University of California, San Diego filed Critical Novartis AG
Publication of CN120225225A publication Critical patent/CN120225225A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
CN202280032073.1A 2021-04-29 2022-04-29 去泛素化酶靶向性嵌合体及相关方法 Pending CN120225225A (zh)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202163181796P 2021-04-29 2021-04-29
US63/181,796 2021-04-29
US202163186739P 2021-05-10 2021-05-10
US63/186,739 2021-05-10
US202163273118P 2021-10-28 2021-10-28
US63/273,118 2021-10-28
US202263311781P 2022-02-18 2022-02-18
US63/311,781 2022-02-18
PCT/US2022/027120 WO2022232634A1 (en) 2021-04-29 2022-04-29 Deubiquitinase-targeting chimeras and related methods

Publications (1)

Publication Number Publication Date
CN120225225A true CN120225225A (zh) 2025-06-27

Family

ID=81748638

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280032073.1A Pending CN120225225A (zh) 2021-04-29 2022-04-29 去泛素化酶靶向性嵌合体及相关方法

Country Status (11)

Country Link
US (1) US20240252655A1 (cg-RX-API-DMAC7.html)
EP (1) EP4329815A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024515828A (cg-RX-API-DMAC7.html)
KR (1) KR20240004584A (cg-RX-API-DMAC7.html)
CN (1) CN120225225A (cg-RX-API-DMAC7.html)
AU (1) AU2022265718A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023022315A2 (cg-RX-API-DMAC7.html)
CA (1) CA3216614A1 (cg-RX-API-DMAC7.html)
IL (1) IL307863A (cg-RX-API-DMAC7.html)
MX (1) MX2023012852A (cg-RX-API-DMAC7.html)
WO (1) WO2022232634A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024220874A2 (en) * 2023-04-21 2024-10-24 Icahn School Of Medicine At Mount Sinai Otub1 small-molecule binders and otub1-recruiting deubiquitinase-targeting chimeras (dubtacs)
WO2024233280A1 (en) * 2023-05-05 2024-11-14 Icahn School Of Medicine At Mount Sinai Heterobifunctional small molecules that deubiquitinylate and stabilize target proteins by recruiting usp7
WO2024264072A2 (en) * 2023-06-23 2024-12-26 Stablix, Inc. Parp inhibitors
CN119350422B (zh) * 2024-12-25 2025-04-04 中国药科大学 一种去泛素化酶靶向嵌合体化合物及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2008109031A (ru) 2005-08-11 2009-09-20 Вертекс Фармасьютикалз Инкорпорейтед (Us) Модуляторы муковисцидозного трансмембранного регулятора проводимости
LT1993360T (lt) 2005-12-28 2017-06-12 Vertex Pharmaceuticals Incorporated N-[2,4-bis(1,1-dimetiletil)-5-hidroksifenil]-1,4-dihidro-4-oksochinolin-3-karboksamido kieta forma
PE20080695A1 (es) 2006-04-27 2008-06-28 Banyu Pharma Co Ltd Derivados de dihidropirazolopirimidinona como inhibidores de quinasa weel
PL2168966T3 (pl) 2007-06-15 2017-06-30 Msd K.K. Pochodna bicykloaniliny
CN102743385B (zh) * 2007-11-16 2014-09-17 沃泰克斯药物股份有限公司 Atp结合盒转运蛋白的异喹啉调节剂
US20110035601A1 (en) 2007-12-21 2011-02-10 University Of Virginia Patent Foundation System, method and computer program product for protecting software via continuous anti-tampering and obfuscation transforms
EP2303885B1 (en) 2008-06-12 2013-07-03 Merck Sharp & Dohme Corp. Process for producing bicycloaniline derivatives
CZ2009620A3 (cs) 2009-09-22 2011-04-06 Ústav makromolekulární chemie AV CR, v.v.i. Surovina pro výrobu polyurethanu a zpusob její výroby z odpadního polyurethanu
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
WO2011133953A1 (en) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions and administrations thereof
KR20150097660A (ko) 2012-12-19 2015-08-26 노파르티스 아게 Cftr 채널을 억제하기 위한 트리시클릭 화합물
CA2895656A1 (en) 2012-12-19 2014-06-26 Novartis Ag Tricyclic compounds as cftr inhibitors
WO2018037350A1 (en) 2016-08-23 2018-03-01 Laurus Labs Limited Solid forms of lumacaftor, process for its preparation and pharmaceutical compositions thereof
CA3103205A1 (en) * 2018-06-13 2019-12-19 Amphista Therapeutics Ltd Bifunctional molecules for targeting uchl5
WO2020069105A1 (en) * 2018-09-27 2020-04-02 Dana-Farber Cancer Institute, Inc. Degraders of wee1 kinase
AU2020224327B2 (en) * 2019-02-21 2022-09-29 Entact Bio Limited Survival-targeting chimeric ( SURTAC) molecules
EP4090371A4 (en) * 2020-01-14 2024-04-03 The Trustees of Columbia University in the City of New York COMPOSITIONS AND METHODS FOR TARGETED PROTEIN STABILIZATION BY RE-ROUTING ENDOGENOUS DEUBIQUITINASES

Also Published As

Publication number Publication date
EP4329815A1 (en) 2024-03-06
CA3216614A1 (en) 2022-11-03
MX2023012852A (es) 2024-01-15
US20240252655A1 (en) 2024-08-01
WO2022232634A1 (en) 2022-11-03
JP2024515828A (ja) 2024-04-10
BR112023022315A2 (pt) 2024-02-20
IL307863A (en) 2023-12-01
AU2022265718A1 (en) 2023-11-02
KR20240004584A (ko) 2024-01-11

Similar Documents

Publication Publication Date Title
JP7005582B2 (ja) ブルトン型チロシンキナーゼ(btk)インヒビターとしての多フルオロ置換化合物
US20240252655A1 (en) Deubiquitinase-targeting chimeras and related methods
RU2687060C2 (ru) Фармацевтические соединения
CN114057771B (zh) 大环化合物及其制备方法和应用
EP3569602B1 (en) Imidazopyrazine compound, preparation method therefor and use thereof
EP3398950B1 (en) Novel kinase inhibitor against wild-type egfr and mutated egfr
KR20130008557A (ko) Cdk4/6의 억제제로서의 중수소화 피롤로피리미딘 화합물
US20200289659A1 (en) Conjugates for treating diseases
RU2632199C2 (ru) Функционализированные производные тиеноиндола для лечения ракового заболевания
AU2020255702B2 (en) Quinolyl-containing compound and pharmaceutical composition, and use thereof
CN121909188A (zh) 一类nsd蛋白降解剂及其用途
US20190084988A1 (en) Wdr5 inhibitors and modulators
CN112243437A (zh) 含丙烯酰基的核转运调节剂及其用途
WO2024220852A2 (en) Tead core inhibitors for cancer therapeutics
KR102938808B1 (ko) Rip2 키나아제 억제제로서의 헤테로아릴 화합물, 이의 조성물 및 용도
CN112341390A (zh) 用于制备靶向组蛋白甲基转移酶ezh2共价抑制剂的化合物及其制备方法和用途
US20250082657A1 (en) Conjugates of chemotherapy agents and tissue-binding small molecules, compositions and methods thereof
US10590101B2 (en) Benzo-N-hydroxy amide compounds having antitumor activity
EP4556465A1 (en) Novel bicyclic pd-l1 inhibitors, preparation methods therefor and medicinal uses thereof
US20250188062A1 (en) Triazine compounds and methods of making and using the same
WO2024097355A1 (en) Deubiquitinase-targeting chimeras and related methods
US20250066353A1 (en) Vanin-1 inhibitors
Calder et al. The Design, Synthesis, and Evaluation of Hypoxia-Activated Prodrugs of the KDAC Inhibitor Panobinostat
EP4653442A1 (en) Polycyclic compound for treating neurological diseases and tumors
HK40120533A (en) Btk inhibitors

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination